The great debate part II: should managed care rely on cost sharing to manage big-ticket biologics?
作者信息
Zitter Mark
机构信息
The Zitter Group, Millburn, NJ 07041, USA.
出版信息
Am J Manag Care. 2006 Apr;12(6 Suppl):S153-8; discussion S167-72; quiz S173-6.
PMID:16613529
Abstract
摘要
相似文献
1
The great debate part II: should managed care rely on cost sharing to manage big-ticket biologics?激烈辩论第二部分：管理式医疗是否应依靠成本分摊来管理高价生物制剂？
Am J Manag Care. 2006 Apr;12(6 Suppl):S153-8; discussion S167-72; quiz S173-6.
2
The case for cost sharing for biologic therapies.生物疗法成本分摊的理由。
Am J Manag Care. 2006 Apr;12(6 Suppl):S159-61; discussion S167-72; quiz S173-6.
3
Balancing quality employee benefits with cost sharing.平衡优质员工福利与成本分摊。
Am J Manag Care. 2006 Apr;12(6 Suppl):S165-6; discussion S167-72; quiz S173-6.
4
The case against excessive cost sharing.反对过度成本分担的理由。
Am J Manag Care. 2006 Apr;12(6 Suppl):S162-4; discussion S167-72; quiz S173-6.
5
The future of prescription drug cost-sharing: real progress or dropped opportunity?处方药费用分摊的未来：是真正的进展还是错失的机遇？
J Manag Care Pharm. 2008 Jan-Feb;14(1):70-82. doi: 10.18553/jmcp.2008.14.1.70.
6
Patient cost sharing: how much is too much?患者费用分担：多少才算过多？
Issue Brief Cent Stud Health Syst Change. 2003 Dec(72):1-4.
7
Medicare formulary coverage for top-selling biologics.医疗保险对畅销生物制剂的处方覆盖范围。
Nat Biotechnol. 2009 Dec;27(12):1082-4. doi: 10.1038/nbt1209-1082.
8
Financial incentives and drug spending in managed care.
LDI Issue Brief. 1999 May;4(1):1-4.
9
Specialty pharmacy management adjusts to new financial realities.专科药房管理适应新的财务现实。
Manag Care. 2013 Apr;22(4):13-4.
10
Copayments dominate drug cost sharing choices.自付费用在药物费用分担选择中占主导地位。
Manag Care. 2012 Nov;21(11):55.
引用本文的文献
1
N-of-1 trials of expensive biological therapies: a third way?昂贵生物疗法的单病例试验：第三条道路？
Arch Intern Med. 2008 May 26;168(10):1030-3. doi: 10.1001/archinte.168.10.1030.
Zotero 插件